vs
美敦力（MDT）与Ross Stores（ROST）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是Ross Stores的1.6倍（$9.0B vs $5.6B），美敦力净利率更高（15.3% vs 9.1%，领先6.2%），Ross Stores同比增速更快（10.4% vs 6.6%），Ross Stores自由现金流更多（$617.8M vs $457.0M），过去两年美敦力的营收复合增速更高（5.3% vs -3.6%）
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
Ross Stores, Inc.是美国知名折扣百货连锁集团，旗下核心品牌为Ross Dress for Less，总部位于加利福尼亚州都柏林，是美国规模最大的平价零售商。截至2024年7月，集团在全美43个州、华盛顿特区、波多黎各及关岛共运营1795家门店，暂未覆盖新英格兰地区及阿拉斯加，另拥有门店数超353家的折扣零售品牌DD's Discounts。
MDT vs ROST — 直观对比
营收规模更大
MDT
是对方的1.6倍
$5.6B
营收增速更快
ROST
高出3.8%
6.6%
净利率更高
MDT
高出6.2%
9.1%
自由现金流更多
ROST
多$160.8M
$457.0M
两年增速更快
MDT
近两年复合增速
-3.6%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.0B | $5.6B |
| 净利润 | $1.4B | $511.9M |
| 毛利率 | 65.8% | 28.0% |
| 营业利润率 | 18.8% | 11.6% |
| 净利率 | 15.3% | 9.1% |
| 营收同比 | 6.6% | 10.4% |
| 净利润同比 | 8.2% | 4.7% |
| 每股收益（稀释后） | $1.07 | $1.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDTROST
| Q4 25 | $9.0B | $5.6B | ||
| Q3 25 | $8.6B | $5.5B | ||
| Q2 25 | $8.9B | $5.0B | ||
| Q1 25 | $8.3B | $5.9B | ||
| Q4 24 | $8.4B | $5.1B | ||
| Q3 24 | $7.9B | $5.3B | ||
| Q2 24 | $8.6B | $4.9B | ||
| Q1 24 | $8.1B | $6.0B |
净利润MDTROST
| Q4 25 | $1.4B | $511.9M | ||
| Q3 25 | $1.0B | $508.0M | ||
| Q2 25 | $1.1B | $479.2M | ||
| Q1 25 | $1.3B | $586.8M | ||
| Q4 24 | $1.3B | $488.8M | ||
| Q3 24 | $1.0B | $527.1M | ||
| Q2 24 | $654.0M | $488.0M | ||
| Q1 24 | $1.3B | $609.7M |
毛利率MDTROST
| Q4 25 | 65.8% | 28.0% | ||
| Q3 25 | 65.0% | 27.6% | ||
| Q2 25 | 64.8% | 28.2% | ||
| Q1 25 | 66.5% | 26.5% | ||
| Q4 24 | 64.9% | 28.3% | ||
| Q3 24 | 65.1% | 28.3% | ||
| Q2 24 | 64.5% | 28.1% | ||
| Q1 24 | 65.6% | 27.3% |
营业利润率MDTROST
| Q4 25 | 18.8% | 11.6% | ||
| Q3 25 | 16.8% | 11.5% | ||
| Q2 25 | 16.1% | 12.2% | ||
| Q1 25 | 19.9% | 12.4% | ||
| Q4 24 | 19.0% | 11.9% | ||
| Q3 24 | 16.1% | 12.5% | ||
| Q2 24 | 12.3% | 12.2% | ||
| Q1 24 | 18.3% | 13.2% |
净利率MDTROST
| Q4 25 | 15.3% | 9.1% | ||
| Q3 25 | 12.1% | 9.2% | ||
| Q2 25 | 11.8% | 9.6% | ||
| Q1 25 | 15.6% | 9.9% | ||
| Q4 24 | 15.1% | 9.6% | ||
| Q3 24 | 13.2% | 10.0% | ||
| Q2 24 | 7.6% | 10.0% | ||
| Q1 24 | 16.3% | 10.1% |
每股收益（稀释后）MDTROST
| Q4 25 | $1.07 | $1.58 | ||
| Q3 25 | $0.81 | $1.56 | ||
| Q2 25 | $0.81 | $1.47 | ||
| Q1 25 | $1.01 | $1.79 | ||
| Q4 24 | $0.99 | $1.48 | ||
| Q3 24 | $0.80 | $1.59 | ||
| Q2 24 | $0.50 | $1.46 | ||
| Q1 24 | $0.99 | $1.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3B | $4.1B |
| 总债务越低越好 | $27.7B | $1.5B |
| 股东权益账面价值 | $48.7B | $5.9B |
| 总资产 | $91.3B | $15.4B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资MDTROST
| Q4 25 | $8.3B | $4.1B | ||
| Q3 25 | $8.1B | $3.8B | ||
| Q2 25 | $9.0B | $3.8B | ||
| Q1 25 | $7.9B | $4.7B | ||
| Q4 24 | $8.0B | $4.3B | ||
| Q3 24 | $7.8B | $4.7B | ||
| Q2 24 | $8.0B | $4.7B | ||
| Q1 24 | $8.3B | $4.9B |
总债务MDTROST
| Q4 25 | $27.7B | $1.5B | ||
| Q3 25 | $26.2B | $1.5B | ||
| Q2 25 | $25.6B | $1.5B | ||
| Q1 25 | $24.0B | $2.2B | ||
| Q4 24 | $24.6B | $2.2B | ||
| Q3 24 | $26.3B | $2.5B | ||
| Q2 24 | $23.9B | $2.5B | ||
| Q1 24 | $24.2B | $2.5B |
股东权益MDTROST
| Q4 25 | $48.7B | $5.9B | ||
| Q3 25 | $47.9B | $5.7B | ||
| Q2 25 | $48.0B | $5.6B | ||
| Q1 25 | $49.4B | $5.5B | ||
| Q4 24 | $48.5B | $5.3B | ||
| Q3 24 | $47.9B | $5.1B | ||
| Q2 24 | $50.2B | $4.9B | ||
| Q1 24 | $51.8B | $4.9B |
总资产MDTROST
| Q4 25 | $91.3B | $15.4B | ||
| Q3 25 | $91.0B | $14.5B | ||
| Q2 25 | $91.7B | $14.3B | ||
| Q1 25 | $90.0B | $14.9B | ||
| Q4 24 | $90.0B | $14.9B | ||
| Q3 24 | $89.7B | $14.7B | ||
| Q2 24 | $90.0B | $14.5B | ||
| Q1 24 | $90.8B | $14.3B |
负债/权益比MDTROST
| Q4 25 | 0.57× | 0.26× | ||
| Q3 25 | 0.55× | 0.26× | ||
| Q2 25 | 0.53× | 0.27× | ||
| Q1 25 | 0.49× | 0.40× | ||
| Q4 24 | 0.51× | 0.42× | ||
| Q3 24 | 0.55× | 0.48× | ||
| Q2 24 | 0.48× | 0.50× | ||
| Q1 24 | 0.47× | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $925.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $457.0M | $617.8M |
| 自由现金流率自由现金流/营收 | 5.1% | 11.0% |
| 资本支出强度资本支出/营收 | 5.2% | 3.7% |
| 现金转化率经营现金流/净利润 | 0.67× | 1.62× |
| 过去12个月自由现金流最近4个季度 | $5.2B | $2.0B |
8季度趋势，按日历期对齐
经营现金流MDTROST
| Q4 25 | $925.0M | $827.1M | ||
| Q3 25 | $1.1B | $668.4M | ||
| Q2 25 | $2.5B | $409.7M | ||
| Q1 25 | $2.6B | $882.6M | ||
| Q4 24 | $958.0M | $513.4M | ||
| Q3 24 | $986.0M | $592.1M | ||
| Q2 24 | $2.8B | $368.9M | ||
| Q1 24 | $2.5B | $948.8M |
自由现金流MDTROST
| Q4 25 | $457.0M | $617.8M | ||
| Q3 25 | $584.0M | $466.6M | ||
| Q2 25 | $2.1B | $202.3M | ||
| Q1 25 | $2.1B | $676.6M | ||
| Q4 24 | $554.0M | $333.0M | ||
| Q3 24 | $466.0M | $394.6M | ||
| Q2 24 | $2.4B | $232.7M | ||
| Q1 24 | $2.1B | $726.4M |
自由现金流率MDTROST
| Q4 25 | 5.1% | 11.0% | ||
| Q3 25 | 6.8% | 8.4% | ||
| Q2 25 | 23.2% | 4.1% | ||
| Q1 25 | 25.3% | 11.4% | ||
| Q4 24 | 6.6% | 6.6% | ||
| Q3 24 | 5.9% | 7.5% | ||
| Q2 24 | 27.4% | 4.8% | ||
| Q1 24 | 26.3% | 12.1% |
资本支出强度MDTROST
| Q4 25 | 5.2% | 3.7% | ||
| Q3 25 | 5.9% | 3.6% | ||
| Q2 25 | 5.1% | 4.2% | ||
| Q1 25 | 5.7% | 3.5% | ||
| Q4 24 | 4.8% | 3.6% | ||
| Q3 24 | 6.6% | 3.7% | ||
| Q2 24 | 5.0% | 2.8% | ||
| Q1 24 | 4.3% | 3.7% |
现金转化率MDTROST
| Q4 25 | 0.67× | 1.62× | ||
| Q3 25 | 1.05× | 1.32× | ||
| Q2 25 | 2.39× | 0.85× | ||
| Q1 25 | 1.99× | 1.50× | ||
| Q4 24 | 0.75× | 1.05× | ||
| Q3 24 | 0.95× | 1.12× | ||
| Q2 24 | 4.25× | 0.76× | ||
| Q1 24 | 1.87× | 1.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
ROST
暂无分部数据
